# Fuhan

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fuhan

- Industry: Healthcare Specialists
- Headquarters: Nanjing, China
- Website: www.fuhanyiliao.com
- Latest round: Series A (Jan 12, 2024)
- Investors on record: 1

## About

Established in 2018 and based in Nanjing, China, Fuhan operates as a technology-focused enterprise dedicated to the research and development of products and services in the field of children's Ophthalmic healthcare. It acquired more than 50 national patents, including more than 20 utility model and invention patents, and more than 10 software copyrights. Fuhan also acquired High-tech Enterprise and Innovative Enterprise titles. In January 2024, it closed series A funding led by returning investor Jolmo Capital.

The company mainly provides ophthalmic wide-area imaging system, which include Kiretem-01, Kiretem Ultra, and Kiretem Mini. Kiretem Ophthalmic Wide-Angle lmaging System is equipment for screening fundus disease of infants and children in clinical practice, which is conducive to early detection of a variety of neonatal congenital eye diseases and fundus lesions. Fuhan also provides intelligent AI-assisted judgment system and baby examination bed. The company's products serve the diagnosis and treatment of eye diseases in newborns, children and surgical patients.

The company will register and launch the first domestic OCT equipment suitable for posterior segment imaging of infants and young children in 2024, and complete the development and promotion of C-end physiological parameter monitors, hospital-end iris dilators and other products in 2025.

## Funding rounds

- Series A, Jan 12, 2024 — Jolmo Capital

## Investors

- Jolmo Capital (https://capitalatlas.ai/funds/jolmo-capital) — Series A